Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 52, Issue 2, 2011, Pages 290-297

  Nagel, Stefan ^a   Venturini, Letizia ^b   Meyer, Corinna ^a   Kaufmann, Maren ^a   Scherr, Michaela ^b   Drexler, Hans G ^a   MacLeod, Roderick A F ^a  

^a DSMZ German Collection of Microorganisms and Cell Cultures ^*  (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

GFI1B; HOXA10; IL7; NMYC; STAT5

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; INTERLEUKIN 7; JANUS KINASE; STAT5 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GFI1B; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR LYL1; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTRO MYOCYTE ENHANCER FACTOR 2C; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME DELETION; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; INHIBITION KINETICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSCRIPTION REGULATION;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MADS DOMAIN PROTEINS; MYOGENIC REGULATORY FACTORS; NEOPLASM PROTEINS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 79551627395     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.537003     Document Type: Article

References (35)

1. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002;1:75-87.
2. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008; 8:380-390.
3. Rothenberg EV, Moore JE, Yui MA. Launching the T-celllineage developmental programme. Nat Rev Immunol 2008; 8:9-21.
4. Duan Z, Horwitz M. Gfi-1 oncoproteins in hematopoiesis. Hematology 2003;8:339-344.
5. Doan LL, Kitay MK, Yu Q, et al. Growth factor independence- 1B expression leads to defects in T cell activation, IL-7 receptor alpha expression, and T cell lineage commitment. J Immunol 2003;170:2356-2366.
6. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M. TAL1/ SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 2004;5:587-596.
7. Zhong Y, Jiang L, Hiai H, Toyokuni S, Yamada Y. Overexpression of a transcription factor LYL1 induces Tand B-cell lymphoma in mice. Oncogene 2007;26:6937-6947.
8. Bain G, Engel I, Robanus Maandag EC, et al. E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas. Mol Cell Biol 1997;17:4782-4791.
9. Kang J, DiBenedetto B, Narayan K, Zhao H, Der SD, Chambers CA. STAT5 is required for thymopoiesis in a development stage-specific manner. J Immunol 2004;173: 2307-2314.
10. Nagel S, Kaufmann M, Drexler HG, MacLeod RA. The ardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2). Cancer Res 2003;63:5329-5334.
11. Soulier J, Clappier E, Cayuela JM, et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood 2005;106:274-286.
12. Nagel S, Meyer C, Quentmeier H, Kaufmann M, Drexler HG, MacLeod RA. MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines. Leukemia 2008;22:600-607.
13. Swanson BJ, Jäck HM, Lyons GE. Characterization of myocyte enhancer factor 2 (MEF2) expression in B and T cells: MEF2C is a B cell-restricted transcription factor in lymphocytes. Mol Immunol 1998;35:445-458.
14. Wilker PR,KohyamaM, SandauMM, et al.Transcription factor Mef2c is required forBcell proliferation and survival after antigen receptor stimulation. Nat Immunol 2008;9:603-612.
15. Stehling-Sun S, Dade J, Nutt SL, DeKoter RP, Camargo FD. Regulation of lymphoid versus myeloid fate 'choice' by the transcription factor Mef2c. Nat Immunol 2009;10:289-296.
16. Schwieger M, Schü ler A, Forster M, et al. Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C. Blood 2009;114:2476-2488.
17. Faber J, Krivtsov AV, Stubbs MC, et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009;113:2375-2385.
18. Drexler HG. Guide to leukemia-lymphoma cell lines. 2nd ed.Braunschweig: DSMZ; 2010 [eBook on CD].
19. Heuser M, Sly LM, Argiropoulos B, et al. Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. Blood 2009;114: 3983-3993.
20. Scherr M, Battmer K, Ganser A, Eder M. Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle 2003;2:251-257.
21. Xu M, Nie L, Kim SH, Sun XH. STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPbeta. EMBO J 2003;22:893-904.
22. Nagel S, Scherr M, Kel A, et al. Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 30-BCL11B enhancers and coregulation by PU.1 and HMGA1. Cancer Res 2007;67:1461-1471.
23. Laurent B, Randrianarison-Huetz V, Marchal V, Mayeux P, Dusanter-Fourt I, Duménil D. High-mobility group protein HMGB2 regulates human erythroid differentiation through trans-activation of GFI1B transcription. Blood 2010;115:687-695.
24. Kawagoe H, Grosveld GC. Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9. Blood 2005;106:4269-4277.
25. Liu T, Jankovic D, Brault L, et al. Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. Leukemia 2010;24:601-612.
26. Slape C, Hartung H, Lin YW, Bies J, Wolff L, Aplan PD. Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation. Cancer Res 2007;67:5148-5155.
27. Bao J, Zervos AS. Isolation and characterization of Nmi, a novel partner of Myc proteins. Oncogene 1996;12:2171-2176.
28. Zhu M, John S, Berg M, Leonard WJ. Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgammamediated signaling. Cell 1999;96:121-130.
29. Monzen K, Ito Y, Naito AT, et al. A crucial role of a high mobility group protein HMGA2 in cardiogenesis. Nat Cell Biol 2008;10:567-574. (Pubitemid 351627376)
30. Pallard C, Stegmann AP, van Kleffens T, Smart F, Venkitaraman A, Spits H. Distinct roles of the phosphatidylinositol 3-kinase and STAT5 pathways in IL-7-mediated development of human thymocyte precursors. Immunity 1999;10:525-535.
31. Goetz CA, Harmon IR, O'Neil JJ, Burchill MA, Johanns TM, Farrar MA. Restricted STAT5 activation dictates appropriate thymic B versus T cell lineage commitment. J Immunol 2005;174:7753-7763.
32. Nagel S, Venturini L, Meyer C, et al. Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines. Leuk Res 2010;34:521-528.
33. Janssen JW, Ludwig WD, Sterry W, Bartram CR. SIL-TAL1 deletion in T-cell acute lymphoblastic leukemia. Leukemia 1993;7:1204-1210.
34. Gekas C, Rhodes KE, Gereige LM, et al. Mef2C is a lineagerestricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis. Blood 2009;113:3461-3471.
35. Wang DZ, Valdez MR, McAnally J, Richardson J, Olson EN. The Mef2c gene is a direct transcriptional target of myogenic bHLH and MEF2 proteins during skeletal muscle development. Development 2001;128:4623-4633.